齐拉西酮与利培酮治疗女性精神分裂症患者对照观察

目的 探讨齐拉西酮与利培酮治疗女性精神分裂症患者的疗效及安全性.方法 采用随机双盲对照研究,将100例女性精神分裂症住院患者随机分为齐拉西酮组、利培酮组,各50例.疗程12周.以阳性与阴性症状量表（PANSS）评定疗效,以治疗中出现的症状量表（TESS）评定不良反应,用世界卫生组织编制的生活质量量表（WHO QOL-100）评定生活质量,同时检测体质量、血糖及催乳素.结果 齐拉西酮组与利培酮组的总体疗效相当;利培酮较齐拉西酮引起的锥体外系反应及抗胆碱能作用发生率高;齐拉西酮对血清催乳素、血糖、体质量影响较利培酮小;齐拉西酮组WHOQOL-100各领域评分均明显改善.结论 齐拉西酮与利培酮疗效相当,不良反应小,能明显改善患者生活质量.

Observation of Ziprasidone and risperidone in the treatment of female patients with schizophrenia

Objective To investigate the efficacy and safety of ziprasidone and risperidone in the treatment of female patients with schizophrenia. Methods 100 female inpatients with schizophrenia were randomly divided into groups ziprasi- done and risperidone group, with 50 cases in each group. To assess the clinical treatment of the symptoms to Scale （TESS） assess adverse reactions with positive and negative syndrome scale （ PANSS）, the quality of life was assessed by the World Health Organization Quality of Life Scale （WHO QOL - 100）, and body weight, blood glucose and prolactin were testes. Re- suits Two groups showed considerable overall effect; risperidone caused more extrapyramidal effects of ziprasidone and a high incidence of anticholinergic effects; ziprasidone on serum prolactin, blood glucose, body mass of small compared risperi- done; ziprasidone group WHOQOL - 100 scores were significantly improved in all areas. Conclusion The efficacy of ziprasidone is same as risperidone, with lower side effects, and can improve the quality of life.